Journal profile · MEDICINE, RESEARCH & EXPERIMENTAL
Biologics-Targets & Therapy
ISSN 1177-5475 · eISSN 1177-5491 · Dove Medical Press · United Kingdom
Biologics-Targets & Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 5.9 (journal website); JCR Q2 (journal website); fully open access; APC about USD 4,320; median 91 days to acceptance (89 articles, last 24 months); acceptance rate 19% (journal website); 56 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Biologics-Targets & Therapy is published by Dove Medical Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Rheumatoid Arthritis Research and Therapies, Psoriasis: Treatment and Pathogenesis and Monoclonal and Polyclonal Antibodies Research, together about 25.3% of its articles. Its main subfields are Rheumatology. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Professor Shein-Chung Chow Biologics: Targets and Therapy is an international, peer-reviewed, open access journal patho-physiological rationale for, and clinical application of, biologic agents and their biosimilars in the management of autoimmune diseases, cancers, or other pathologies where a molecular target can be identified. Biologics: Targets and Therapy will no longer consider meta-analyses for publication. Specific topics covered by the journal include:• Gene therapy• Cell therapy• Antibody-based therapy• Blood components• Vaccines• Hormones• Cytokines and growth factors• Toxins• Peptides This journal is characterized by the rapid reporting of original research, reviews, basic science, clinical studies and commentaries. When considering submission of a paper utilizing publicly available data, authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors’ own data through replication in an original sample. The journal does not accept study protocols. The journal will consider case reports only if they make a valuable and original contribution to the literature. Updated 16 July 2025
From the journal's Aims & Scope
Research area (LetPub): MEDICINE, RESEARCH & EXPERIMENTAL
Editor-in-chief Shein-Chung ChowPublisher website
Editorial board by country: 3 in mainland China (about 12%); most named United States 12, Mainland China 3, India 2, Italy 2, Saudi Arabia 2 (25 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Rheumatoid Arthritis Research and TherapiesMedicine12.7%
- Psoriasis: Treatment and PathogenesisImmunology and Microbiology6.3%
- Monoclonal and Polyclonal Antibodies ResearchMedicine6.3%
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology6.1%
- Systemic Lupus Erythematosus ResearchMedicine5.8%
- Spondyloarthritis Studies and TreatmentsMedicine5.8%
- Inflammatory Bowel DiseaseBiochemistry, Genetics and Molecular Biology5.4%
- Chronic Lymphocytic Leukemia ResearchMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
SJR, CiteScore, Impact FactorPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 5.9Publisher website ·
- 5-year impact factor (publisher)
- 4.5Publisher website ·
- CiteScore 2026-06
- 4.5LetPub ·
- CiteScore (publisher) 2025
- 0.88Publisher website ·
- SJR 2026-06
- 0.99LetPub ·
- SNIP 2026-06
- 0.88LetPub ·
- h-index
- 58OpenAlex ·
- i10-index
- 336OpenAlex ·
- 2-year mean citedness
- 4.22OpenAlex ·
- Self-citation rate
- 2.2%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 52LetPub ·
- Downloads per year (publisher)
- 56,812Publisher website ·
Articles by year OpenAlex count · 606 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 23 | 23 | 6 |
| 2025 | 56 | 56 | 144 |
| 2024 | 35 | 35 | 331 |
| 2023 | 17 | 17 | 82 |
| 2022 | 18 | 18 | 272 |
| 2021 | 40 | 40 | 1,632 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
91 daysMedian, submission to acceptance · P25–P75 70 days – 118 days
- Acceptance to online
- median 13 days (89 articles)
- Submission to online
- median 107 days
- Sample
- 89 articles with submission and acceptance dates (91 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 19%Publisher website ·
- Desk decision
- 46 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,320 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — | |
| LetPub | USD 2,990 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted3
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- original researchOriginal ResearchLength not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics, Open access
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1177-5475
- Electronic ISSN
- 1177-5491
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Biologics-Targets & Therapy
What CAS zone is Biologics-Targets & Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Biologics-Targets & Therapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Biologics-Targets & Therapy?
The journal's website gives an impact factor of 5.9 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4.5, h-index 58.
How long does peer review take at Biologics-Targets & Therapy?
Based on the dates recorded on 89 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 91 days (interquartile range 70–118 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 19%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Biologics-Targets & Therapy in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Biologics-Targets & Therapy based?
Of the 25 board members whose country the journal's board page names, 3 (about 12%) are in mainland China; the countries named most often are United States (12), Mainland China (3) and India (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Biologics-Targets & Therapy?
According to LetPub and DOAJ records, Biologics-Targets & Therapy is indexed in ESCI, Scopus and DOAJ.
Is Biologics-Targets & Therapy open access, and what is the APC?
Biologics-Targets & Therapy is a fully open-access journal. APC about USD 4,320.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .